explore -WSS

explore

author：leisure time 2025-09-07 21:55:12 - browse：38

Dr. Peter Bach — Peter Bach, shown at the 2019 STAT summit, is now chief medical officer of Delfi. Emilie Pickering for STAT

Delfi Diagnostics, a well-funded startup in the burgeoning field of creating blood tests to detect cancer, said on Monday that it is launching a new test, FirstLook Lung, to try to identify people who could most benefit from lung cancer screening.

The approach represents a new one in the field of liquid biopsy, in which DNA fragments in blood are used to detect or learn about tumors. Grail, another company developing a blood test for cancer screening, has insisted that its product would be best used to detect multiple cancers at once. Other companies, including Exact Sciences and Freenome, are developing tests that would focus on detecting colorectal cancer. But Delfi appears to be the first to focus first on lung cancer, the leading cause of cancer death.

Delfi’s executives, in an interview with STAT, were clear that they view the initial launch as an opportunity to gather information, and not a real commercial coming out. The test will likely become available in limited ways with specific partners and will not initially be covered by insurance. Delfi declined to reveal a specific price, but said that its early access customers, which it is not yet disclosing, will be able to use FirstLook Lung for several hundred dollars. Such a rollout does not require approval from the Food and Drug Administration, which Delfi does not have.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medical records are filled with copy
Next article： Gritstone Bio's cancer vaccine test, and more on Novartis' deal

WSS

Unique patient identifier: Experts argue the benefits, pitfalls

Devoted Health’s losses in Medicare Advantage persist

AstraZeneca stays mum on Medicare drug pricing negotiations

Changes to biosimilar regulatory framework must prioritize patients

Texas Medical Board asked to define abortion emergency exception

Gene therapy for Afghan refugees’ infant will be fully covered

entertainment

explore

knowledge

Novavax promises a turnaround & Lilly roils the obesity market

How AI helped researchers track recovery from depression

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Drug for rare kidney disease narrowly misses mark in clinical trial

New air purifier tech could be key to improving indoor air quality

CDC's new outbreak response network to include Northeastern

After affirmative action ruling, medical educators look to 'holistic review'

Cano Health’s bankruptcy is a warning for Medicare Advantage

In Memoriam: Notable people who died in 2023

Gene therapy for Afghan refugees’ infant will be fully covered

leisure time

Gene therapy for Afghan refugees’ infant will be fully covered

Medicare Advantage plans can’t deny care with AI, CMS warns

Johnson & Johnson sued for allegedly overpaying for workers' drugs

Readout Newsletter: Amgen, Regeneron, BGI Group and more

Lasker Awards 2023: Winners in biomedical research

AstraZeneca stays mum on Medicare drug pricing negotiations

focus

knowledge

hotspot

focus